Posts Tagged ‘budesonide’

Children whose asthma improved while taking steroid drugs for many years cannot expect the same benefits after stopping the use, as per new results from a comprehensive childhood asthma study.

The study, which was published in advance online publication of the Journal of Pediatrics, revealed that children using steroids during the trial and now in their late teens showed no differences in terms of asthma control when compared with the children who received the placebo.

From News-Medical.Net:

Inhaled corticosteroids such as budesonide have been shown to be the most effective form of anti-inflammatory treatment for asthma by controlling symptoms and improving pulmonary function. Results from the original CAMP trial showed that using budesonide twice daily led to fewer hospitalizations and urgent care visits, fewer days in which additional asthma  medications were needed and a reduced need for albuterol, a fast-acting drug for relief of acute asthma symptoms. Using nedocromil twice daily reduced urgent care visits and courses of oral steroids for severe symptoms, but did not affect the number of hospitalizations, symptoms or airway responsiveness.

Although the patients had fewer symptoms five years after stopping the daily medication, Strunk cautions that doesn’t mean that they can stop using asthma medications altogether or that their asthma is cured.

Robert C. Strunk, M.D., a Washington University pediatrician at St. Louis Children’s Hospital and lead author of the study, remarked that kids with asthma can experience better control as they grow older.

Chronic asthmatic patients can now benefit from a new treatment option that can help them to manage their ailment in an easy, effective manner with a single prescribed inhaler that contains two medicines as per a new review.

It is worth noting that the use of both beta2-agonist (formoterol) and a low-dose corticosteroid (budesonide) in a single inhaler and this review evaluated the new inhaler’s effectiveness.

From News-Medical.Net:

“Encouraging people to use their preventive medication is important, as it is often the case that people with asthma default on their inhaled corticosteroids,” said lead reviewer Christopher Cates, M.D., at the Community Health Sciences of St. George’s at the University of London. “This is partly because inhaled steroids do not make an immediate difference to asthma symptoms.”

In most studies, participants had treatment with a single inhaler – one inhalation of 80/4.5 milligrams of budesonide/formoterol twice daily, and as needed. Patients in the control groups used their prescribed inhaled corticosteroid with a separate reliever inhaler. Cates and his colleague evaluated three studies that included more than 4,200 adults and adolescents with chronic asthma. One study also included 224 children.

The Cochrane reviewers found no significant reduction in the number of asthma exacerbations that required hospitalization among the patients who used single inhaler therapy.

Carlos Camargo, M.D., an associate professor of medicine at Harvard Medical School, said that this single-inhaler therapy is a new approach to chronic asthma treatment is expected to provide great relief but requires further research before it can be recommended.

Children with asthma and being administered with steroids in the younger age but discontinuing the usage after some time may not experience the same benefits as with steroid usage, according to results from a comprehensive childhood asthma study.

This study finding came from the Childhood Asthma Management Program (CAMP) clinical trial that involved more than 1,000 children with mild-to-moderate asthma. These children were divided into three groups of which one received placebo, second one received nedocromil (an inhaled non-steroid medication), and the third one received twice-daily budesonide and an inhaled corticosteroid. All the participating groups also received albuterol, a bronchodilator, and oral corticosteroids for treating asthma symptoms.

From News-Medical.Net:

Inhaled corticosteroids such as budesonide have been shown to be the most effective form of anti-inflammatory treatment for asthma by controlling symptoms and improving pulmonary function. Results from the original CAMP trial showed that using budesonide twice daily led to fewer hospitalizations and urgent care visits, fewer days in which additional asthma medications were needed and a reduced need for albuterol, a fast-acting drug for relief of acute asthma symptoms. Using nedocromil twice daily reduced urgent care visits and courses of oral steroids for severe symptoms, but did not affect the number of hospitalizations, symptoms or airway responsiveness.

Although the patients had fewer symptoms five years after stopping the daily medication, Strunk cautions that doesn’t mean that they can stop using asthma medications altogether or that their asthma is cured.

The study findings are considered to provide new insights to members of the medical fraternity when it comes to formulation of new asthma treatment plans.

Individuals suffering from chronic asthma are likely to benefit from a new treatment option that can help them manage their health effectively with a single prescribed inhaler including two medicines, as per a new review.

The involved researchers were studying the effectiveness of both a low-dose corticosteroid (budesonide) and beta2-agonist (formoterol) in a single inhaler.

The review appeared in an issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization evaluating research in all health care aspects.

From News-Medical.Net:

“Encouraging people to use their preventive medication is important, as it is often the case that people with asthma default on their inhaled corticosteroids,” said lead reviewer Christopher Cates, M.D., at the Community Health Sciences of St. George’s at the University of London. “This is partly because inhaled steroids do not make an immediate difference to asthma symptoms.”

In most studies, participants had treatment with a single inhaler – one inhalation of 80/4.5 milligrams of budesonide/formoterol twice daily, and as needed. Patients in the control groups used their prescribed inhaled corticosteroid with a separate reliever inhaler. Cates and his colleague evaluated three studies that included more than 4,200 adults and adolescents with chronic asthma. One study also included 224 children.

The Cochrane reviewers found no significant reduction in the number of asthma exacerbations that required hospitalization among the patients who used single inhaler therapy.

It was remarked by Cates that one benefit of combined inhalers is that inhaled corticosteroids can be administered on an automatic basis with the beta-agonist when it comes to relieving symptoms.